RxDoctor Payments Data

Cameron Kemal, MD

Cardiovascular Disease · Clearwater, FLNPI 1609309715

Payments from drug & device makers

$3,219in general payments, 2019–2025

Across 172 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$510
  • Pfizer$501
  • Novartis$468
  • Amgen$359
  • Alnylam Pharmaceuticals Inc.$235
  • Boehringer Ingelheim$208
  • plus $939 from 14 others

What the payments were for

  • Food & beverage$3,10596%
  • Education$1144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,219 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$272,416
Medicare patients
1,349
Services billed
3,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten19$147,188
JardianceEmpagliflozin70$76,401
XareltoRivaroxaban71$64,987
EliquisApixaban47$59,892
Repatha SureclickEvolocumab41$36,288
FarxigaDapagliflozin Propanediol32$32,708
EntrestoSacubitril/Valsartan24$31,914
Repatha SyringeEvolocumab46$21,643
MounjaroTirzepatide11$9,105
BrilintaTicagrelor12$8,323
Metoprolol Succinate211$2,506
Rosuvastatin Calcium180$2,102
Ezetimibe48$1,330
Atorvastatin Calcium110$925
Potassium Chloride26$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$510$147,18819 claims
Boehringer IngelheimJardiance$208$76,40170 claims
Johnson & JohnsonXarelto$94$64,98771 claims
PfizerEliquis$501$59,89247 claims
AstraZenecaFarxiga, Brilinta$61$41,03144 claims
NovartisEntresto$468$31,91424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →